Our Story.
More than seven years ago, in a bar in Houston, four longtime friends gathered over beer and conversation. One was a cancer biologist and professor at MD Anderson Cancer Center. The other three, mathematicians and computer scientists were visiting from Silicon Valley.
What began as a casual evening quickly turned into a bold question: Could artificial intelligence transform the way we treat cancer?
The AI experts described how advanced algorithms could analyze routine diagnostic tissue images, detect subtle patterns in tumor morphology, and correlate them with treatment outcomes. In theory, AI could help guide the right therapy for the right patient—using information already present in standard pathology slides.
To the biologist, this sounded almost impossible. But as the discussion deepened, so did the realization: the science was ready. The real challenge would be convincing the clinical world.
Determined to explore the idea further, the biologist arranged a meeting with his Department Chair, a respected clinician and leader in prostate cancer therapy. The Chair offered a clear and practical starting point: if AI could accurately predict Gleason Grade (GG) from diagnostic tissue images, it would speak the language clinicians already trust. Despite its limitations, Gleason Grade remains one of the most validated and widely used predictors of prostate cancer outcomes.
That insight defined the company’s first mission.
From that moment, PATHOMIQ was born at the intersection of biology, mathematics, and clinical reality. What started as a conversation among friends became a focused effort to bring AI into everyday cancer decision-making, beginning with prostate cancer.
Today, PATHOMIQ partners with Myriad Genetics to advance prostate cancer biomarkers for disease prognosis, continuing the journey that began with a simple question in a Houston bar:
What if we could see more in every tissue image?
Our mission is to accelerate precision medicine by unlocking the hidden patterns within pathology data patterns that can inform outcomes, predict treatment responses, and even reveal underlying genetic mutations.
At the heart of our innovation is a first-of-its-kind Phenotype Atlas: a powerful, AI-driven platform that has learned high-level phenotypic information across the full spectrum of cancer pathology. Unlike anything before it, our atlas is both comprehensive and adaptive — trained on thousands of pathology slides across multiple tissue types and sourced from a wide array of leading medical institutions. By combining expert pathologist insight with cutting-edge machine learning, we’ve created a tool that can be deployed rapidly to new use cases, even when only a small amount of outcome data is available.
Our founder’s motivation for starting this company is deeply personal. Having witnessed the toll cancer takes on loved ones, he committed to building a company that could make a real impact, bringing clarity, speed, and better outcomes to patients and clinicians alike.
With our phenotype atlas, we aim to equip the world with a smarter, more responsive way to fight it—one that learns, adapts, and evolves with each new case.
PATHOMIQ AI, headquartered in Silicon Valley, USA, was founded by a multidisciplinary team of outstanding biomarker discovery researchers, data scientists, and clinicians with 100+ man-years of experience in their areas of specialty.
CEO & Co-Founder
Chief Medical Officer
Head of Pathology &
Co-Founder
